ADCT
ADCT clinical trials: ADC Therapeutics SA
Every trial on ClinicalTrials.gov where ADC Therapeutics SA is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 35
- Trials linked
- 21
- As lead sponsor
- 14
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ADCT on the catalyst calendar · ADCT registry changes
- Primary completion Jun 25, 2026ActualPhase 1NCT05660395A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large...ADC Therapeutics S.A. · Diffuse Large B-Cell LymphomaTerminatedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2027Sponsor estimatePhase 1NCT04970901A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in...ADC Therapeutics S.A. · B-Cell Non-Hodgkin LymphomaActive, not recruitingADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2026ActualPhase 3NCT04384484Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse...ADC Therapeutics S.A. · Relapsed Diffuse Large B-Cell LymphomaActive, not recruitingADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 13, 2024ActualPhase 1NCT04972981A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected...ADC Therapeutics S.A. · Advanced Solid TumorsCompletedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 17, 2025ActualPhase 1NCT05389462A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid TumorsADC Therapeutics S.A. · Advanced Solid TumorsTerminatedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 22, 2024ActualPhase 2NCT05144009A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell...ADC Therapeutics S.A. · Diffuse Large B-cell LymphomaTerminatedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2022ActualPhase 1NCT03621982Study of ADCT-301 in Patients With Selected Advanced Solid TumorsADC Therapeutics S.A. · Head and Neck Cancer Squamous Cell CarcinomaTerminatedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2023ActualPhase 2NCT04052997Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin LymphomaADC Therapeutics S.A. · Relapsed Hodgkin LymphomaCompletedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 8, 2022ActualPhase 1/Phase 2NCT03684694Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell LymphomaADC Therapeutics S.A. · Diffuse Large B-Cell LymphomaTerminatedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 25, 2022ActualPhase 2NCT04699461Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory...ADC Therapeutics S.A. · Relapsed Follicular LymphomaTerminatedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 24, 2020ActualPhase 2NCT03589469Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaADC Therapeutics S.A. · Diffuse Large B-Cell Lymphoma RefractoryCompletedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2024Sponsor estimateNo phase registeredNCT05160064Long-term Registry of Patients Treated With Loncastuximab TesirineADC Therapeutics S.A. · B-Cell LymphomasWithdrawnADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 11, 2024Sponsor estimatePhase 1NCT04974996A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With...ADC Therapeutics S.A. · Diffuse Large B-Cell LymphomaWithdrawnADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 27, 2020ActualPhase 1NCT03685344Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular LymphomaADC Therapeutics S.A. · Diffuse Large B-Cell LymphomaTerminatedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 24, 2019ActualPhase 1NCT02432235Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin LymphomaADC Therapeutics S.A. · Hodgkin LymphomaCompletedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT04705454Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaADC Therapeutics S.A. · Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)No longer availableADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 3, 2018ActualPhase 1NCT02669264Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)ADC Therapeutics S.A. · Acute Lymphoblastic LeukemiaTerminatedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 21, 2019ActualPhase 1NCT02669017Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)ADC Therapeutics S.A. · Non-Hodgkin LymphomaCompletedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 5, 2018ActualPhase 1NCT03125200Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) ExpressionADC Therapeutics S.A. · Breast CancerTerminatedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 11, 2019ActualPhase 1NCT03700294Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid TumorsADC Therapeutics S.A. · Advanced Solid TumorsTerminatedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 29, 2018ActualPhase 1NCT02588092Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic...ADC Therapeutics S.A. · Acute Myeloid LeukemiaTerminatedADCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 1, 2027Sponsor estimatePhase 2NCT05600686Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell LymphomaUniversity of California, Davis · Double-Expressor LymphomaSuspendedADCTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2030Sponsor estimatePhase 1/Phase 2NCT07573436Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)University of Utah · Post-transplant Lymphoproliferative DisorderRecruitingADCTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT05971251Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic LeukemiaUniversity of Alabama at Birmingham · Chronic Lymphocytic LeukemiaActive, not recruitingADCTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 2NCT06788964Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma...University of Utah · Relapsed or Refractory Large B-cell LymphomaRecruitingADCTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 10 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner